The SLC17A (solute carrier family 17) family comprises a group of membrane transport proteins that play key roles in the transport of a variety of substrates, including organic anions, phosphates, and neurotransmitters. Members of this family are primarily known as phosphate transporters (SLC17A1-4) and vesicular glutamate transporters (VGLUTs, SLC17A5-7). The phosphate transporters are involved in the renal reabsorption of phosphate, a critical process for maintaining phosphate homeostasis, bone mineralization, and overall metabolic function. The VGLUTs are crucial in the central nervous system, where they transport glutamate into synaptic vesicles, facilitating excitatory neurotransmission. The signaling and function of SLC17A transporters are essential in various physiological processes, from bone health to nerve communication, and their dysfunction is implicated in several diseases, including neurological disorders and phosphate metabolism abnormalities.
Targeting SLC17A signaling for disruption or inhibition with small molecules enables a more detailed understanding of the diverse roles these transporters play in physiological and pathological processes. By inhibiting specific SLC17A transporters, researchers can delineate their individual contributions to phosphate homeostasis and neurotransmitter regulation. Such targeted approaches are crucial in elucidating the mechanisms of diseases related to phosphate imbalance or glutamate signaling disorders. Additionally, the use of small molecule inhibitors can shed light on the potential targets within the SLC17A family for conditions like osteoporosis or neurodegenerative diseases.
VER TAMBIÉN ....
Items 11 to 20 of 23 total
Mostrar:
| Nombre del producto | NÚMERO DE CAS # | Número de catálogo | Cantidad | Precio | MENCIONES | Clasificación |
|---|---|---|---|---|---|---|
Sofosbuvir | 1190307-88-0 | sc-482362 | 25 mg | $143.00 | 1 | |
Un inhibidor de la ecto-ATPasa, que puede alterar los niveles extracelulares de ATP, afectando indirectamente a SLC17A. | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | $92.00 $348.00 | 46 | |
Un protonóforo, interrumpe los gradientes de protones, influyendo potencialmente en la función de SLC17A. | ||||||
Niflumic acid | 4394-00-7 | sc-204820 | 5 g | $31.00 | 3 | |
Un antiinflamatorio no esteroideo, puede afectar indirectamente a los canales y transportadores iónicos como el SLC17A. | ||||||
Probenecid | 57-66-9 | sc-202773 sc-202773A sc-202773B sc-202773C | 1 g 5 g 25 g 100 g | $27.00 $38.00 $98.00 $272.00 | 28 | |
Inhibe competitivamente varios transportadores de aniones, reduciendo potencialmente la función de los miembros de la familia SLC17. | ||||||
Phloridzin dihydrate | 7061-54-3 | sc-215708 sc-215708A | 250 mg 1 g | $48.00 $117.00 | ||
Inhibe los transportadores dependientes de sodio, podría reducir la captación competitiva de fosfato. | ||||||
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $149.00 $210.00 $714.00 $2550.00 $10750.00 $21410.00 $40290.00 | 5 | |
Inhibe de forma no selectiva varias proteínas de membrana, alterando posiblemente el transporte relacionado con SLC17A. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $28.00 $37.00 | 18 | |
Inhibe los transportadores de aniones indirectamente al afectar a la síntesis de prostaglandinas, alterando la dinámica del transporte renal. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $40.00 | ||
Un diurético de asa que inhibe la NKCC2, puede tener efectos secundarios sobre el transporte de fosfato. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $107.00 $224.00 | 9 | |
Al igual que la furosemida, inhibe la NKCC2, lo que podría influir indirectamente en la actividad de la SLC17A. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Afecta a la inositol monofosfatasa provocando cambios en el transporte de aniones, podría alterar la función de SLC17A. | ||||||